Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 4/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19834107 | 0.95 | MGLL (0.59) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19833963 | 0.91 | MGLL (0.54) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19834068 | 0.89 | MGLL (0.70) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19833834 | 0.87 | MGLL (0.58) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19834151 | 0.85 | MGLL (0.67) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19833808 | 0.84 | MGLL (0.69) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19833754 | 0.84 | MGLL (0.84) | MGLLMEN1KMT2AHTR1DHTR1A | |
| SCHEMBL19834060 | 0.84 | MGLL (0.73) | MGLLNR3C2HTR1DHTR1AHTR1B | |
| SCHEMBL19834140 | 0.84 | MGLL (0.63) | MGLLMEN1KMT2ANR3C2HTR1D | |
| SCHEMBL19833841 | 0.83 | MGLL (0.74) | MGLLHTR1DHTR1AHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-3279191-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-02 | — | — | EP | disclosed |
| US-10106556-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-23 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-03-22 | — | — | US | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
| EP-3279191-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2018-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079756-A1 | HETEROCYCLIC COMPOUND | MAG, ACHE, HTT | MGLL 129/4885MEN1 141/4885KMT2A 1125/4885 |
| US-10106556-B2 | Heterocyclic compound | MAG, ACHE, HTT | MGLL 129/4885MEN1 141/4885KMT2A 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.